Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Fig. 2

Mean daily faecal bile acid excretion (a) at baseline and days 11–12, and (b) change from baseline to days 11–12. Baseline was days − 2 and − 1 for this data set. Data are from the pharmacodynamic analysis set. b.i.d., twice daily; CI, confidence interval; q.d., once daily; SD, standard deviation

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us